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Abst rac t
Introduction: Adalimumab and etanercept are drugs used in anti-TNF therapy in patients with psoriasis and psori-
atic arthritis. Despite the molecular targeting of these drugs, the loss of pharmacological response to treatment is 
observed in patients. The development of personalized medicine makes it possible to use not only clinical param-
eters of disease severity, but also molecular marker systems.
Aim: The aim of the study was to evaluate the changes in TNF-α, TNFR1, and TNFR2 expression in relation to 
parameters of disease severity (PASI, BSA, DAS28) in patients treated with adalimumab and etanercept. We have 
attempted to determine whether changes in the TNF-α, TNFR1, and TNFR2 expression profile may be a useful mo-
lecular marker of the therapeutic potential of anti-TNF drugs.
Material and methods: The study group consisted of 3 patients initially treated with adalimumab, followed by 
etanercept. The control group included 20 healthy volunteers. The expression profile of TNFR1 and TNFR2 was de-
termined at the mRNA level, while TNF-α expression was evaluated at the transcriptome and proteome levels using 
the RT-qPCR method (transcriptional activity assay) and MALDI-TOF MS (protein level assessment).
Results: Depending on the drug, different expression profiles of the studied cytokines are observed. 
Conclusions: The obtained data indicate that TNF-α, TNFR1, and TNFR2 may be useful markers of the efficacy 
of anti-TNF therapy, thus complementing clinical parameters.
Key words: anti-TNF therapy, psoriasis, molecular marker, resistance in therapy, personalized medicine.
Introduction
Psoriasis is a multifactorial, pro-inflammatory disease 
with a complex immunopathogenesis, affecting 1–3% of 
the population, usually between 20–30 and 50–60 years 
of age [1–3]. A characteristic clinical symptom is para-
keratosis [2], while at the molecular level, changes in the 
concentration profile of cytokines e.g. tumour necrosis 
factor-α (TNF-α), interleukins (IL-12, IL-23, IL-17), trans-
forming growth factor β (TGF-β) are observed [1, 4].
Depending on psoriasis severity, conventional ther-
apy including local and systemic treatment is used, and 
in the absence of its effects, patients are qualified for 
anti-cytokine therapy [4, 5]. This type of therapy includes 
two important groups of drugs: TNF-α inhibitors (adali-
mumab, etanercept) and IL-12/23 inhibitor (ustekinumab) 
[6, 7]. It is recommended for patients with PASI > 10 or 
BSA > 10 (parameters of disease severity) and meeting 
also the other requirements set out in the qualification 
for the drug programme [5, 8]. These drugs are character-
ized by unique specificity of action as well as quick and 
long-lasting effect [8–10].
Adalimumab is a fully human monoclonal antibody 
that has the ability to neutralize both membrane-bound 
and soluble forms of TNF-α, thereby interrupting the sig-
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nal pathway activated by this cytokine. The effectiveness 
of treatment measured with the PASI-75 index is over 
60% with therapy lasting more than 60 weeks. In turn, 
etanercept is a fusion protein consisting of soluble TNF-α 
receptor linked to the Fc region of IgG1. This drug has 
the ability to bind to the circulating soluble form of the 
cytokine. It is administered on a continuous basis and the 
effectiveness of treatment is assessed after 12 weeks of 
pharmacotherapy [11–13].
Anti-TNF therapy is one of the most effective meth-
ods of treating proinflammatory diseases, however it is 
associated with numerous adverse effects and loss of 
drug susceptibility [11, 12]. Therefore, personalization of 
therapeutic strategies is an extremely important aspect 
of diagnosis and treatment. The techniques used in mo-
lecular biology helping to develop modern methods of 
treatment are becoming an increasingly common tool in 
clinical diagnostics. Learning about changes at the mo-
lecular level is also important due to the fact that they 
precede alterations at the phenotypic level, which cre-
ates the possibility of early detection of drug resistance, 
allowing to improve the therapeutic strategy [14–16].
Aim 
The aim of this study was to determine the possibility 
of using changes in the expression profile of TNF-α and 
its receptors TNFR1 and TNFR2 as complementary mo-
lecular markers of the efficacy of anti-TNF therapy (adali-
mumab, etanercept) in patients with psoriasis during the 
4-year follow-up. The occurrence or lack of association 
between molecular parameters and indices of disease 
severity (PASI, DAS28, BSA) was also examined.
Material and methods
The study material consisted of the whole blood col-
lected every 12 weeks (one monitoring) from 3 patients 
with diagnosed psoriatic arthritis initially treated with 
adalimumab followed by etanercept (patients A, B, C). 
The deviation from this rule was the result of patient’s 
absence during study material collecting. The clinical and 
molecular characteristics of these patients were taken 
into account. For selected samples, the TNF-α expression 
was determined at the protein level. The control group 
consisted of 20 healthy volunteers (9 women, 11 men), 
in which changes in the expression profile of the studied 
cytokines were determined at the mRNA level. The mean 
age in the study group was 41 ±10 years and 46 ±10 years 
in the control group. All patients provided informed con-
sent to participate in the study.
The first step of molecular analysis was the isola-
tion of total RNA from whole blood using the FENOZOL 
reagent (A&A Biotechnology, Gdańsk, Poland) in accor-
dance with the protocol. Then, a quantitative reverse 
transcription PCR (RT-qPCR) was performed for mRNA 
of TNF-α, TNFR1, TNFR2 with β-actin (ACTB) as an en-
dogenous control. The RT-qPCR was carried out with the 
use of the QuantiTect SYBR Green RT-PCR Kit (Qiagen, 
Valencia, CA, USA) as recommended by the manufactur-
er. Detection of serum TNF concentration was performed 
with MALDI-TOF Mass Spectrometry using the AXIMA 
Performance MALDI-TOF
2
 spectrometer (Shimadzu, 
Kyoto, Japan) according to the protocol. Clinical analysis 
was carried out every 12 weeks based on PASI, BSA, and 
DAS28 parameters. 
Ethical approval
Consent of the Bioethics Commission of the Medical 
University of Silesia in Katowice/Poland no. KNW/0022/
KB1/59/I/13/14.
Statistical analysis
Statistica 12.0 PL (StatSoft, Tulsa, Oklahoma, USA) 
was used to perform statistical analysis (p < 0.05). 
Spearman’s rank correlation coefficient was determined 
between the TNF-α expression profile and clinical pa-
rameters (PASI, BSA, DAS28) and among them for each 
patient.
Results
The expression profile of TNF-α, TNFR1 and TNFR2 
(the number of mRNA copies per μg of total RNA), con-
centration of TNF-α protein and parameters of disease 
severity (PASI, DAS28, BSA) during the 4-year follow-up 
for each patient are presented in Table 1.
In the control group, the mean value of expression 
of the analysed genes was as follows: TNF-α: 1149048 
±1554419; TNFR1: 547826 ±777004; and TNFR2: 1037 
±1731.
When monitoring response to adalimumab therapy in 
patient A, no TNF-α expression was observed (0 copies/μg 
of RNA), which changed when the drug was switched to 
etanercept. The highest transcriptional activity of TNF-α 
is observed until the sixth monitoring and gradually de-
creases reaching a relatively low level of expression from 
the twelfth monitoring. By analysing the expression of 
TNFR1 and TNFR2, it can be noted that during treatment 
with adalimumab, TNFR2 is more expressed than TNFR1 
(TNFR1 < TNFR2), which changes during etanercept ther-
apy (TNFR1 > TNFR2) as reported in the control group. 
The level of TNF protein in selected samples was rela-
tively constant. The decrease in the values of all clinical 
parameters describing the severity of the disease was 
also reported. 
At the end of adalimumab therapy, an increased 
TNF-α expression and PASI, BSA values were observed 
in patient B before the drug was changed to etanercept. 
In addition, the expression profile of TNFR1 and TNFR2 
during treatment with each anti-TNF drug shows similar-
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Table 1. Molecular and clinical characteristics of patients A, B, and C treated with adalimumab and etanercept




TNF-α TNFR1 TNFR2 PASI BSA DAS28
Patient A:
 Adalimumab 1 0 14 329  12.9 36 3.02
 Etanercept 0 11182692 30567 16 241 18 34 3.98
1 9684314 3785 1138 262 15 28 1.26
 2 411848 26348 14 193 19 21 3.23
 3 1202857 47807 14 201 16 19 1.61
 4 4767045 3619 238 309 17 19 1.47
 5 3516327 10367 252 226 5 10 2.09
 6 16558333 35517 88  5 10 2.72
 7 22850 16558 136  4 4 1.61
 8 65517 16358 377  7 10 1.61
 9 24850 12502 92  5 12 2.09
 10 55733 11317 199  5 9 1.12
 11 64050 57000 170  4 7 1.61
 12 134 198500000 11683  4 7 2.09
 13 119 0 223  4 7 1.12
 14 0 137 3338  4 7 1.12
Patient B:
 Adalimumab 1 0 14 329  5.7 30 4.27
2 1598 53300 58950 17 14 31 3.77
 Etanercept 0 5588506 1506 134 114 17 27 4.26
1 2466949 1900 11 333 15 26 4.26
2 37333 12165 232 0 16 20 4.34
3 102217 25333 224 253 11 17 4.22
4 83867 45167 143  2 10 3.95
5 52183 25983 215  3 10 3.61
6 102217 25333 224  4 7 3.31
7 63550 159533 1557  4 9 4.49
8 83867 45167 143  4 9 3.01
9 0 0 14  4 9 3.08
10 0 0 83  4 10 3.42
11 0 0 16988  4 10 3.37
Patient C:
Adalimumab 1 0 0 0  10 20 4.18
2 43 8450 4087 0 8.5 9 3.85
3 7117 1934 780667 0 7.2 13 3.83
4 97500 125889 2331  8.8 14 4.33
5 37524 211647 207  3.8 8 4.08
6 0 0 189121  9.6 15 4.48
Etanercept 1 10463 5372 763  9 14 3.77
2 9173 12198 59  10 15 3.99
3 411167 403333 2163  9 14 3.46
4 170167 188000 1623  5 13 3.63
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ity to that noted in patient A, although for the last three 
monitorings of etanercept therapy, an increase in tran-
scriptional activity of TNFR2 can be observed compared 
to TNFR1, as in adalimumab treatment. In the initial 
stages of monitoring the effectiveness of etanercept, it 
can be noted that TNF-α expression is silenced from the 
ninth monitoring. Analysis at the proteome level showed 
a relatively high increase in TNF expression in the first 
monitoring period after treatment change and the ten-
dency to silence it after drug administration. Based on 
clinical parameters of monitoring the effectiveness of 
therapy, their higher values can be observed in treat-
ment with adalimumab. During the etanercept therapy, 
a gradual reduction in disease severity is reported based 
on the indicators of clinical response to treatment.
In patient C, the evaluation of the efficacy of adalim-
umab therapy consisted of six monitorings, during which 
no TNF expression at the protein level was reported, 
while the observation of etanercept therapy included 
four monitorings. The ratio of TNFR1 to TNFR2 was the 
same as previously reported. With regard to TNF-α, the 
heterogeneity of its expression is observed. During the 
monitoring of the effectiveness of adalimumab, there is 
a jump in the values of clinical parameters, which remain 
at a relatively constant level up to the fourth monitoring 
of etanercept therapy. Comparison of the transcriptional 
activity of the examined genes between the study and 
control groups shows a lower expression of TNF-α among 
patients on anti-cytokine therapy. Analysis of the TNFR1 
> TNFR2 expression ratio indicates a similar trend in the 
number of transcripts of these genes among healthy vol-
unteers and patients during etanercept therapy and the 
reverse one during adalimumab treatment.
The next part of the study was to examine the pos-
sible occurrence of statistically significant (p < 0.05) 
Spearman’s correlation between the expression of the 
analysed genes and parameters of disease severity (PASI, 
BSA, DAS28) for each patient and the relationship be-
tween clinical indicators. We observed correlations be-
tween mentioned parameters only during etanercept 
therapy (patients A and B) and for patient C during treat-
ment with adalimumab and etanercept. The correlation 
between TNF-α and TNFR1 expression was reported for 
patient B (rs = 0.534719) and patient C (rs = 0.851852 
for adalimumab; rs = 0.88571 for etanercept), while for 
patient C the correlation between TNF-α and TNFR2 
expression was found during etanercept therapy (rs = 
0.82857). Our results showed a correlation between gene 
expression and clinical parameters as follows: TNF-α and 
PASI (patient A, rs = 0.728716), TNF-α and BSA (patient A, 
rs = 0.758441), TNFR1 and DAS28 (patient A, rs = 0.654799; 
patient C, rs = –0.811679 for adalimumab). We also ob-
served a correlation between PASI and BSA in patient A 
(rs = 0.935905), patient B (rs = 0.642966), patient C on 
adalimumab (rs = 0.42857) and between BSA and DAS28 
in patient B (rs = 0.606988).
Discussion
The studies performed as part of this work were 
conducted for patients with psoriatic arthritis admit-
ted to the anti-TNF drug programme. These patients 
were initially qualified for treatment with adalimumab 
based on the interview, examination and parameters of 
disease severity. However, according to accepted stan-
dards, a phenotypic loss of susceptibility to adalimumab 
based on the PASI, BSA, and DAS28 was observed af-
ter some time of pharmacotherapy [17, 18]. Therefore, 
the decision was made to change the anti-TNF drug to 
etanercept. In our study, we focused on determining 
the possibility of links between molecular indicators of 
inflammation (TNF-α, TNFR1, TNFR2) and indicators of 
clinical response to treatment. Furthermore, we have es-
tablished the possibility of earlier detection of emerging 
drug resistance based on the expression of the analysed 
molecular markers. This course of action seems justified 
due to the increasingly complex individual approach to 
the patient [19] and the fact that molecular alterations 
precede phenotypic changes [14–16]. The effectiveness 
of anti-TNF therapy is evidenced by the fact that we ob-
served a lower TNF-α expression in the study group than 
in the control group. Research conducted by Shveta et al. 
confirms the involvement of TNF-α in the pathogenesis 
of psoriasis and in combination with our observations 
demonstrate the validity of anti-TNF therapy [20]. Nev-
ertheless, our study indicates the insufficient efficacy 
of adalimumab treatment, which results in a change 
of the drug to etanercept, without negating the impor-
tance of using these drugs in anti-TNF therapy. Patients 
received the same doses of adalimumab and etanercept 
according to the guidelines. The control of clinical and 
molecular parameters was performed every 12 weeks. 
In our previous work on the dermal fibroblast model we 
showed that changes in the gene expression pattern 
under the influence of the anti-TNF drug are already ob-
served after 2-hour exposure of the cells to the drug [21]. 
It is extremely important to find a universal molecular 
marker of response to the drug and the development 
of the inflammatory process [22, 23]. In addition to the 
determination of the clinical parameters and changes 
in TNF-α, TNFR1, and TNFR2 expression at the mRNA 
level for all periods of monitoring the efficacy of anti-
TNF therapy, the level of TNF-α protein was evaluated in 
selected samples. Analysis of the transcriptional activ-
ity of TNF-α receptors showed that TNFR1 expression is 
lower than TNFR2 during treatment with adalimumab, 
while for etanercept therapy and in the control group it 
is reversed. It is believed that changes in the expression 
of TNF-α receptors may be indicators of the severity of 
inflammatory changes in the joints [24]. Gola et al. also 
reported a higher TNFR2 expression compared to TNFR1 
when exposing RPTEC cells to AmB-Cu2+, noting that the 
observed changes may result from the less toxic effect of 
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AmB-Cu2+ [25], also indicating the induction of repair pro-
cesses by this form of the drug [26]. However, regarding 
the changes observed in our study, it can be concluded 
that anti-TNF therapy affects the genes associated with 
the TNF signal pathway by altering the expression of re-
ceptors for this cytokine. Moreover, the profile of changes 
in receptors expression depends on the type of anti-TNF 
drug and the observed TNFR1/TNFR2 ratio may result 
from a different structure and mechanism of action of 
adalimumab and etanercept [4, 9, 10, 27]. However, given 
the fact that we noted a higher transcriptional activity of 
TNFR1 than TNFR2 in the control group, etanercept does 
not appear to be toxic.
During the whole period of etanercept treatment, 
the level of TNF-α expression was higher than during 
adalimumab therapy. However, the observation of the 
therapeutic potential of adalimumab has been carried 
out for a relatively short time. On the one hand, changes 
in the transcriptional activity of TNF-α during treatment 
with adalimumab may be related to its mechanism of 
action, but on the other hand they may be a molecular 
manifestation of drug resistance. The increase in TNF-α 
expression observed in the first monitorings after the 
inclusion of etanercept may result from the extension 
of the inflammatory process to peripheral joints. TNF-α 
stimulates the secretion of extracellular matrix metal-
loproteinases (MMPs), responsible for the remodelling 
of extracellular matrix of the articular cartilage, from 
infiltrating inflammatory cells [27]. In addition, previous 
reports confirming an elevated concentration of TNF-α 
during etanercept therapy associated with its long half-
life in serum should be taken into account [28]. Moreover, 
it is suggested that the level of TNF-α and its receptors 
can be used as an indicator for selecting the appropri-
ate dose of etanercept and the effectiveness of therapy 
[29, 30]. It would also explain a relatively constant con-
centration of TNF protein in our study group. We evalu-
ated TNF-α expression at the proteome level during the 
first few monitoring periods to assess the relationship of 
its expression at the mRNA and protein levels, however, 
based on the obtained data, it is difficult to determine 
this association.
TNFR1 is present on the majority of nucleated cells 
and mediates the cascade of reactions leading to apop-
tosis, whereas TNFR2 is present only on certain cells and 
participates in T cell proliferation [31, 32]. The changes 
observed with respect to these receptors may indicate 
that various biological processes dominate depending 
on the anti-TNF drug (adalimumab, etanercept). It would 
suggest that adalimumab mainly stimulates signalling 
cascades associated with the induction of T cell prolif-
eration, while etanercept leads to programmed cell death 
[31, 32]. Our study showing the increased expression of 
TNFR2 compared to TNFR1 during etanercept therapy 
seems to confirm its efficacy. The key factor hindering 
the effective treatment of psoriasis is the fact that psori-
atic keratinocytes are resistant to apoptosis and that this 
process affects the immune system disorders observed in 
psoriasis [33, 34]. For this reason, the increased participa-
tion of TNFR1 and the pro-apoptotic pathways may be-
come a crucial element in the effectiveness of treatment, 
indicating a positive therapeutic effect. It should be not-
ed that changes in the expression of TNF-α and its recep-
tors may result from the emergence of drug resistance 
and possibly also from the interaction of interferon g 
(IFNG) [35], which increases TNF-α secretion and induces 
its receptors expression [36, 37]. It may explain the in-
crease in the transcriptional activity of this gene when 
the anti-TNF therapeutic strategy is changed. During mo-
lecular observation of patients, relatively large fluctua-
tions in the expression of the analysed genes between 
consecutive administration times of the next dose can be 
noted. It may result from individual variability manifested 
by a different rate of drug metabolism [38, 39]. It was 
observed that people suffering from plaque psoriasis are 
characterized by a faster rate of drug metabolism depen-
dent on the CYP2D6 genotype [40]. As part of this work, 
we determined the relationship between disease severity 
indices (PASI, DAS28, BSA) and molecular parameters of 
the severity of inflammation. We noted a positive cor-
relation between TNF-α and PASI, TNF-α and BSA, which 
are indicators informing about the body surface area cov-
ered by psoriatic lesions. We also found a correlation be-
tween TNFR1 and DAS28, a parameter for assessing the 
inflammation severity in the joints. It is worth noting that 
etanercept is dedicated to patients with psoriatic arthri-
tis, and the observed profile of TNFR1 expression during 
therapy with this drug seems to indicate its therapeutic 
potential and the possibility of using TNFR1 as a marker 
of the severity of joint changes, whereas TNF-α better 
defines the severity of skin lesions. It can be concluded 
that with the rise in the number of copies of the TNF-α or 
TNFR1 transcripts, the PASI, BSA, and DAS28 parameters 
increase and thus effective anti-TNF therapy should aim 
to reduce the expression of cytokines. Serefican et al. 
also indicated a higher level of TNF-α expression in the 
group of patients with psoriasis compared to the control 
group and found a statistically significant positive cor-
relation between the expression of TNF-α and PASI [41]. 
Shveta et al. [20] observed a decrease in the PASI index 
and TNF-α concentration after treatment of patients 
with psoriasis. However, on the basis of our study, the 
decrease or increase in the expression of the analysed 
genes does not correlate with the multiplicity of chang-
es in clinical parameters, therefore the determination 
of TNF-α, TNFR1 and TNFR2 expression should be con-
sidered as a valuable complementary study, indicating 
a tendency of the patient’s response to treatment. We 
observed a higher level of TNF-α protein than described 
by Korczowska-Łącka et al. in patients with ankylosing 
spondylitis [42], which may be due to the modulation of 
the cytokine expression by the drug and simultaneous 
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occurrence of joint and skin symptoms of psoriasis in 
our study group.
A full analysis of the changes in expression at the 
transcriptome and proteome levels along with the clini-
cal parameters and individual approach to the patient 
creates the possibility to increase the effectiveness and 
safety of pharmacotherapy.
Conclusions
The efficacy, safety and success of the therapy de-
pend on the selection of appropriate markers to monitor 
the response to the drug. TNF-α, TNFR1, and TNFR2 seem 
to be good complementary markers of the advancement 
of inflammatory processes including plaque psoriasis 
and psoriatic arthritis. They also allow to determine the 
effectiveness of treatment and increase the precision of 
earlier detection of emerging drug resistance in anti-TNF 
therapy.
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